Show simple item record

Generic competition and market exclusivity periods in pharmaceuticals

dc.contributor.author Grabowski, HG
dc.contributor.author Kyle, M
dc.date.accessioned 2013-04-23T17:06:35Z
dc.date.issued 2007-06-01
dc.identifier.issn 0143-6570
dc.identifier.uri https://hdl.handle.net/10161/6727
dc.description.abstract In this paper we examine generic competition and market exclusivity periods for pharmaceuticals experiencing their initial generic entry between 1995 and 2005. We find that generic competition has increased over several dimensions. First, an increasing number of drugs are subject to generic entry, including drugs with relatively modest annual average sales. Second, drugs with larger sales attract more generic entrants and have shorter market exclusivity periods than smaller selling drugs. Third, blockbuster drugs with annual sales in excess of $1 billion have experienced significant decreases in their market exclusivity periods in recent years. We also find that Hatch-Waxman Act patent challenges have negatively affected market exclusivity periods over the 1995 to 2005 period. Copyright © 2007 John Wiley & Sons, Ltd.
dc.publisher Wiley
dc.relation.ispartof Managerial and Decision Economics
dc.relation.isversionof 10.1002/mde.1356
dc.title Generic competition and market exclusivity periods in pharmaceuticals
dc.type Journal article
duke.contributor.id Grabowski, HG|0099498
pubs.begin-page 491
pubs.end-page 502
pubs.issue 4-5
pubs.organisational-group Duke
pubs.organisational-group Economics
pubs.organisational-group Trinity College of Arts & Sciences
pubs.publication-status Published
pubs.volume 28
dc.identifier.eissn 1099-1468


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record